EASL-EASD-EASO关于resmetirom与司美格鲁肽用于MASH靶向治疗的指导
该联合指导针对代谢功能障碍相关脂肪性肝炎(MASH)成人,提出resmetirom(80 mg/100 mg口服)和司美格鲁肽(2.4 mg皮下每周一次)的用药推荐,涵盖候选者选择、启动、监测与停药。推荐非肝硬化MASH且纤维化2-3期成人接受药物治疗,并结合结构化生活方式干预和合并症优化管理。司美格鲁肽在肥胖、2型糖尿病或心血管病高风险者中可能优先,resmetirom可在无肥胖或已用/不耐受GLP-1RA者中优先。
要点
- 非肝硬化MASH且纤维化2-3期成人推荐药物联合生活方式干预。
- 司美格鲁肽可能优先用于肥胖、2型糖尿病或心血管高风险者。
- resmetirom可优先用于无肥胖或已用/不耐受GLP-1RA者。
核心结论
- 推荐非肝硬化MASH且纤维化2-3期成人接受resmetirom或司美格鲁肽治疗,并结合生活方式干预和合并症管理。
- 药物选择应个体化,根据偏好、潜在风险及心肾代谢特征决定。
- MASH肝硬化患者两种药物安全但不应作为MASH靶向治疗,直至有进一步数据确立肝脏获益。
研究设计与样本
- 欧洲肝病学会、欧洲糖尿病研究学会和欧洲肥胖研究学会联合制定的指导文件。
主要发现
- 非侵入性肝纤维化检测(VCTE 10-20 kPa、MRE 3.1-5.0 kPa或ELF 9.8-11.3)可替代肝活检识别MALO高风险患者。
- 司美格鲁肽因心代谢获益,在肥胖、2型糖尿病、确诊心血管病或高心血管风险成人中可能优先。
- resmetirom可在无肥胖或已接受/不耐受GLP-1RA的个体中优先。
- 司美格鲁肽治疗期间建议进行营养和肌少症评估,使用纤维化NITs进行纵向疗效评估。
关键数值与推荐
- 药物治疗推荐用于非肝硬化MASH且纤维化2-3期成人(基于NITs或活检)。
- resmetirom剂量为80 mg/100 mg口服。
- 司美格鲁肽剂量为2.4 mg皮下每周一次。
- VCTE 10-20 kPa、MRE 3.1-5.0 kPa或ELF 9.8-11.3可用于识别MALO高风险患者。
临床怎么用
- 使用NITs(VCTE、MRE或ELF)识别纤维化高风险患者以考虑药物治疗。
- 根据肥胖、2型糖尿病、心血管病及慢性肾病等心肾代谢特征个体化选择药物。
- 治疗期间进行结构化的安全性和有效性监测,包括营养和肌少症评估。
- MASH肝硬化患者不应将resmetirom或司美格鲁肽作为靶向治疗。
局限性
- 两种药物的长期减少MALO的有效性尚在研究中。
- MASH肝硬化患者使用resmetirom或司美格鲁肽的肝脏获益需进一步数据确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) are at risk of cardiometabolic complications and major adverse liver-related outcome (MALO), including cirrhosis, cancer, and liver transplantation. Non-invasive tests (NITs) for hepatic fibrosis, including vibration-controlled transient elastography (VCTE), magnetic resonance elastography (MRE), or enhanced liver fibrosis (ELF) score, can replace liver biopsy to identify patients at high risk of MALOs (e.g. VCTE 10-20 kPa, MRE 3.1-5.0 kPa, or ELF 9.8-11.3), in which pharmacotherapy may be considered. Following approval by regulatory agencies, this joint EASL-EASD-EASO guidance provides updated recommendations for the use of resmetirom (80 mg/100 mg per os) and semaglutide (2.4 mg subcutaneously weekly) in MASH, covering treatment candidate selection, treatment initiation, monitoring, and discontinuation. Pharmacotherapy is recommended for adults with non-cirrhotic MASH and fibrosis stages 2-3 (based on NITs or biopsy), alongside structured lifestyle intervention and optimised comorbidity management. Treatment selection should be individualised according to preferences, potential risks, and cardio-renal-metabolic profile, including presence of obesity, type 2 diabetes (T2D), cardiovascular, and chronic kidney disease. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), may be preferred in adults with obesity or T2D as well as with established cardiovascular disease or high cardiovascular risk because of its cardiometabolic benefits, whereas resmetirom may be prioritised in individuals without obesity or those already receiving or intolerant to GLP-1RAs. Additional recommendations include structured safety and efficacy monitoring such as nutritional and sarcopenia assessment during semaglutide or use of fibrosis NITs for longitudinal response criteria. Ongoing studies are evaluating the long-term effectiveness of both agents to reduce MALOs. In adults with MASH cirrhosis, resmetirom or semaglutide appear safe but should not be used as MASH-targeted treatment, until further data establish liver-related benefits.
引用
- EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy. J Hepatol. 2026. PMID: 42805503. doi:10.1016/j.jhep.2026.08.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。